United States Drug Patent 5,326,570: Claims, Scope, Expiration, and Carbamazepine Patent Landscape

U.S. Patent No. 5,326,570 protects a multipart oral carbamazepine dosage form combining immediate-release, sustained-release, and enteric-release units in one therapeutic system. Its broadest independent system claim requires all three release profiles. The patent also claims tablets, capsules, pellets, dosage amounts of approximately 400 to 600 mg, 12-hour exposure, blood-level control, surfactants, organic acids, coating levels, and a 6-to-10-hour sustained-release interval.[1]

The patent issued on July 5, 1994. Because it belongs to the pre-Uruguay Round patent-term regime, its ordinary term was 17 years from issuance. On that basis, U.S. Patent 5,326,570 expired on July 5, 2011, absent an unusual term adjustment, extension, or later enforceable continuation right. The patent itself therefore does not present a current U.S. infringement barrier.

What invention does U.S. Patent 5,326,570 protect?

The patent protects a single oral carbamazepine delivery system containing three pharmacokinetic components:

Component	Claimed function
Immediate-release unit	Provides initial carbamazepine availability
Sustained-release unit	Releases carbamazepine over approximately 6 to 10 hours
Enteric-release unit	Delays release until exposure to intestinal conditions
Combined dosage form	Provides therapeutic carbamazepine exposure over approximately 12 hours

The patent is directed to release-profile architecture rather than to carbamazepine as a chemical compound. Carbamazepine itself was an established active pharmaceutical ingredient long before the patent’s filing and cannot be monopolized by this patent.

The core technical concept is the combination of release units within one administered composition. The units may be incorporated into a tablet, capsule, or single dosage form. The claims also contemplate multiparticulates or pellets, particularly pellets filled into a capsule.

How broad is claim 1 of U.S. Patent 5,326,570?

Claim 1 is the principal system claim. It requires:

A drug delivery system for oral carbamazepine administration.
A sustained-release unit containing carbamazepine.
An immediate-release unit containing carbamazepine.
An enteric-release unit containing carbamazepine.
A therapeutically effective combined amount of carbamazepine.

The claim does not expressly require a particular tablet size, capsule size, polymer, enteric coating, surfactant, dissolution profile, or carbamazepine dose. Those limitations appear in dependent claims.

The claim is broad in formulation design but narrow in release architecture. A competing product would generally need to practice all three claimed release modes to fall within the literal scope of claim 1. A conventional extended-release carbamazepine tablet with no separate immediate-release and enteric-release populations would not satisfy claim 1 literally.

What does “unit” mean in the patent claims?

The claims use “unit” functionally. A unit is a portion of the dosage system having a specified release behavior and containing carbamazepine. The patent does not limit the unit to a particular physical shape.

Possible implementations include:

Coated pellets;
Granules;
Beads;
Matrix particles;
Tablet layers;
Capsule-filled multiparticulates; and
Separate populations of particles compressed into a tablet.

The physical form does not remove the requirement for the three distinct release functions.

What do claims 2 through 11 add?

Claims 2 through 11 principally narrow the delivery system by adding administration, dosage-form, dose, duration, and pharmacokinetic limitations.

Claims	Subject matter
2	Method of treating a patient by administering the system of claim 1
3	Components present in a tablet
4	Components present in a capsule
5	Components present in a single dosage form
6	Components in pellet form within a single dosage form
7	Pellet-based dosage form is a capsule
8	Therapeutically effective amount over 12 hours
9	Approximately 400 to 600 mg carbamazepine
10	Blood-level variation no greater than 60% over 12 hours
11	Blood-level variation no greater than 20% over 12 hours

Claims 3 through 7 are physical-form limitations. They are narrower than claim 1 and would be relevant where an accused product uses a tablet, capsule, or pellet-filled capsule.

Claims 8 through 11 introduce performance limitations. These limitations create potential proof issues because infringement may require dissolution, pharmacokinetic, or clinical testing rather than only inspection of the product’s composition.

The phrase “about 400 mg to about 600 mg” is materially broader than a single 400 mg or 600 mg strength in some claim-construction contexts, but the scope would depend on the specification, prosecution history, and accepted measurement tolerances. The blood-level claims also use relative performance thresholds that could produce disputes over sampling intervals, patient populations, fed or fasted conditions, and calculation methodology.

What do claims 12 through 17 protect?

Claims 12 through 17 add formulation and manufacturing limitations.

Surfactant and organic-acid limitations

Claim 12 requires a surfactant in each of the three units. Claim 14 identifies sodium lauryl sulfate as the surfactant.

Claim 13 requires an organic acid in both the sustained-release and enteric-release units to maintain an acidic environment. Claim 25 repeats substantially the same limitation for the method claims.

These limitations are directed to dissolution and solubility control. Carbamazepine has limited aqueous solubility, and the inclusion of a surfactant or acidic microenvironment can affect wetting, dissolution, and release consistency.

A product using a different surfactant would not literally satisfy claim 14, although it could still implicate claim 12 if it contains another surfactant. A product that uses no surfactant would avoid claims 12, 14, 23, and 24 but could still fall within claim 1.

Percentage composition and coating limitations

Claim 15 requires the following approximate weight ranges:

Unit	Claimed range
Sustained-release unit	5.0% to 25.0% w/w
Immediate-release unit	15.0% to 70.0% w/w
Enteric-release unit	10.0% to 50.0% w/w

Claim 16 adds coating ranges:

Coated unit	Claimed coating range
Sustained-release unit	1.0% to 25.0% w/w
Enteric-release unit	1.0% to 15.0% w/w

These claims may be important in product-by-process or formulation comparison work. The relevant question is how the percentages are calculated: relative to the complete dosage form, the coated unit, the uncoated core, or the coating material. The specification and prosecution history would control that interpretation.

Claim 17 requires the sustained-release unit to release carbamazepine over approximately 6 to 10 hours. This is narrower than claim 1 and could be tested through dissolution methods, but the precise test conditions remain important.

What do claims 18 through 25 cover?

Claims 18 through 25 are independent and dependent method claims. Claim 18 requires orally administering a composition containing:

An immediate-release carbamazepine unit;
A sustained-release carbamazepine unit; and
An enteric-release carbamazepine unit.

Unlike claim 2, claim 18 does not expressly depend on claim 1. It is therefore an independently drafted method pathway, although it recites substantially the same three-unit architecture.

Claims 19 through 22 add:

Carbamazepine blood levels of approximately 4 to 12 micrograms per milliliter;
At least 12 hours of exposure;
A combined dose of approximately 400 to 600 mg;
No more than 60% blood-level variation; and
In one claim, no more than 20% variation.

Claims 23 through 25 add surfactant and organic-acid requirements.

For enforcement, a method claim requires evidence that the accused product was administered or directed for administration in a manner meeting the limitations. A formulation manufacturer may present less direct exposure to method-claim liability than a party that markets, labels, or administers the product for the claimed treatment method. The patent’s expiration eliminates that practical issue for current U.S. activity.

When did U.S. Patent 5,326,570 lose exclusivity?

U.S. Patent 5,326,570 expired on July 5, 2011 under the ordinary 17-year-from-issuance term applicable to qualifying pre-June 8, 1995 applications.[1,2]

Event	Date
Patent issued	July 5, 1994
Ordinary statutory term	17 years from issuance
Expiration	July 5, 2011
Current enforceability	Expired

Patent expiration is separate from FDA regulatory exclusivity. Any five-year new chemical entity exclusivity, three-year clinical-investigation exclusivity, pediatric extension, or other FDA exclusivity would arise under the Federal Food, Drug, and Cosmetic Act and would not extend the patent’s ordinary enforceability period.[3]

There is no biosimilar pathway for carbamazepine. Carbamazepine is a small-molecule active ingredient regulated through abbreviated new drug applications, not a biologics license application and biosimilar approval pathway.

What is the Orange Book status of U.S. Patent 5,326,570?

The Orange Book lists patents and exclusivity information associated with approved drug products. Historical Orange Book listings may have identified U.S. Patent 5,326,570 in connection with an extended-release carbamazepine product, but an expired patent no longer blocks an ANDA applicant from relying on a Paragraph III certification to that patent.[4]

The practical regulatory consequences are:

The patent cannot support a current Paragraph IV litigation strategy.
A generic applicant would not need to wait until the 2011 expiration date.
Any 30-month stay tied to a Paragraph IV certification would have been a historical issue, not a current barrier.
Current approval analysis must focus on any later, unexpired listed patents and applicable regulatory exclusivity.

For a present-day product review, the Orange Book should be checked for the specific reference product and dosage form because listings attach to approved products, not merely to the active ingredient.

Which competing carbamazepine products are relevant?

The principal U.S. competitive set historically included immediate-release carbamazepine products and extended-release products.

Product type	Typical release profile	Relevance to Patent 5,326,570
Immediate-release tablets	Rapid release, repeated dosing	Usually lacks the claimed three-unit architecture
Immediate-release suspension	Rapid oral release	Generally outside the claims
Conventional extended-release tablets	Prolonged release from one matrix or coated system	May lack separate enteric and immediate-release units
Multiparticulate extended-release capsules	Multiple pellet populations	Potentially closer to the claim structure
Three-population delivery system	Immediate, sustained, and enteric release	Closest technical match

Carbatrol extended-release capsules are the product most closely associated with the multiparticulate carbamazepine technology protected by this patent family. Tegretol-XR is a competing extended-release carbamazepine product, but a competing product’s commercial extended-release status does not establish that it practices the specific immediate-release, sustained-release, and enteric-release combination claimed here.

A proper infringement comparison would require the product’s formulation, pellet populations, coating materials, dissolution data, label, and regulatory chemistry, manufacturing, and controls information.

What generic entry risks existed before patent expiration?

Before July 5, 2011, the main generic-entry risks were formulation-specific rather than active-ingredient-specific.

Paragraph IV challenge risk

An ANDA applicant could have challenged the patent by asserting that it was:

Invalid;
Not infringed; or
Unenforceable.

Potential technical positions would have included:

The generic lacks an enteric-release carbamazepine unit;
The generic uses a single matrix rather than three distinct units;
The release behavior does not satisfy the claimed sustained-release or enteric-release limitations;
The formulation falls outside the claimed percentage ranges;
The product does not meet the blood-level or 12-hour limitations;
The claims are obvious over multiparticulate drug-delivery references; or
The specification does not adequately support or enable the full claim scope.

A Paragraph IV certification could trigger patent litigation under 21 U.S.C. § 355(j)(5)(B)(iii), potentially creating a 30-month stay of approval under the statutory framework then applicable.[3]

Generic launch scenarios

Before expiration, a generic applicant had three principal paths:

File a Paragraph III certification and await patent expiration.
File a Paragraph IV certification and litigate.
Design around the three-unit architecture or avoid listed claims through a different release mechanism.

After expiration, the patent no longer constrains any of those formulation strategies.

How strong was the patent estate?

The patent was strongest against a product using the same multiparticulate release concept: a single capsule or tablet containing carbamazepine populations designed for immediate, sustained, and delayed intestinal release.

Its strongest claim was claim 1 because it established the central combination without requiring specific excipients, percentages, or dosage form. Claims 3 through 7 strengthened coverage for commercial capsule and pellet implementations. Claims 12 through 17 created narrower positions around surfactants, organic acids, coating weights, component ratios, and release time.

Its weaknesses included the following:

The core concept was limited to a combination of three release modes.
Carbamazepine was known.
Multiparticulate and enteric-release technologies were established formulation tools.
Several claims depended on approximate numerical ranges.
Blood-level claims could be difficult to prove consistently.
The patent had a finite pre-URAA term and expired in 2011.

The patent’s historical commercial value likely came from its fit with a branded extended-release carbamazepine product rather than from broad control over all carbamazepine extended-release formulations.

What manufacturing and intellectual-property barriers remain?

U.S. Patent 5,326,570 no longer creates a manufacturing barrier. Current barriers may instead arise from:

Later patents covering a specific commercial product;
Proprietary pellet coating processes;
Release-testing methods;
Manufacturing know-how;
Product-specific formulation trade secrets;
Regulatory sameness requirements;
Bioequivalence failure;
Complex multiparticulate manufacturing capability; and
Patent rights in jurisdictions where corresponding family members had different expiration dates.

The key commercial distinction is between patent freedom to operate and regulatory approval feasibility. A generic manufacturer can avoid this expired patent and still face substantial development risk from dissolution variability, food-effect differences, dose proportionality, content uniformity, and bioequivalence requirements.

What patent litigation and settlement issues affected the product?

The expiration of Patent 5,326,570 removes any current U.S. litigation exposure under its claims. Historical litigation or settlement agreements involving the patent would require review of the relevant court docket and agreement terms. The patent number alone does not establish whether a particular ANDA litigation resulted in a settlement, authorized generic arrangement, license, or judgment.

Any historical settlement analysis should distinguish:

Litigation over Patent 5,326,570 itself;
Litigation over continuation or related patents;
FDA listing disputes;
Product liability cases; and
Commercial agreements unrelated to patent validity or infringement.

A settlement involving a later patent could have affected generic entry even after the expiration of Patent 5,326,570. Conversely, expiration of this patent would not terminate separate contractual rights or licenses covering other patents, know-how, or trademarks.

Key Takeaways

U.S. Patent 5,326,570 claims a carbamazepine system combining immediate-release, sustained-release, and enteric-release units.
Claim 1 is the central composition claim and requires all three release components.
The patent covers tablets, capsules, pellets, single dosage forms, dose ranges, blood-level control, surfactants, organic acids, coating levels, and release timing through dependent claims.
Claims 18 through 25 provide an independent method-claim pathway.
The patent issued July 5, 1994 and ordinarily expired July 5, 2011.
It does not present a current U.S. patent barrier to generic carbamazepine development.
Carbamazepine is a small molecule, so biosimilar analysis is not applicable.
Current freedom-to-operate analysis must focus on later patents, product-specific Orange Book listings, manufacturing know-how, and regulatory bioequivalence requirements.
The historical infringement risk was highest for multiparticulate products using three distinct carbamazepine release populations in one dosage form.

Frequently Asked Questions

Does U.S. Patent 5,326,570 cover all extended-release carbamazepine products?

No. It requires immediate-release, sustained-release, and enteric-release carbamazepine units in the claimed system. A product using only a sustained-release matrix generally would not meet the literal requirements of claim 1.

Can a generic manufacturer rely on the expiration of Patent 5,326,570?

Yes. The patent expired on July 5, 2011 under its ordinary statutory term. The manufacturer must still evaluate later patents, Orange Book listings, bioequivalence, and manufacturing rights.

Does a carbamazepine tablet infringe if it contains coated pellets?

Only if the pellets collectively satisfy the claim limitations. Pellet form alone is not enough. The product would need the required immediate-release, sustained-release, and enteric-release carbamazepine units.

Are the blood-level limitations required for every infringement case?

No. They are limitations of claims 10, 11, 19, 21, and 22. Claim 1 does not require the specific 60% or 20% blood-level variation limits.

Is a license needed to practice the formulation described in Patent 5,326,570?

Not from this expired patent. A license may still be relevant for later patents, proprietary manufacturing processes, trade secrets, or contractual rights associated with a commercial product.

References

U.S. Patent No. 5,326,570. (1994). Drug delivery system for the oral administration of carbamazepine. United States Patent and Trademark Office.
35 U.S.C. § 154. (2024). Contents and term of patents; provisional rights.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j). (2024). Abbreviated applications for new drugs.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	185268	⤷ Start Trial
Canada	2114014	⤷ Start Trial
Germany	69230112	⤷ Start Trial
Denmark	0660705	⤷ Start Trial
European Patent Office	0660705	⤷ Start Trial
Spain	2137948	⤷ Start Trial
Greece	3031448	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,326,570

Summary for Patent: 5,326,570